TM

Treace Medical Concepts, Inc.

TMCIHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$212.7M
+1.6% YoY
Net Income
-$59.0M
-5.8% YoY
EBITDA
-$43.1M
-2.4% YoY
Free Cash Flow
-$5.8M

Scan Results

Daily timeframe
DateIndicatorDetails
Jun 29 MACD Negative CrossoverHistogram -0.0017 — negative momentum
Jun 27 MACD Negative CrossoverHistogram -0.0026 — negative momentum
About Treace Medical Concepts, Inc.

Headquartered within the healthcare sector, Treace Medical Concepts, Inc. focuses on Medical Devices services and products. Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The $302.3M market capitalization puts TMCI squarely in small-cap range for its industry. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.

Key stats
Market Cap$302.3M
Fwd P/E-5.18
EPS$-1.04
Beta1.38
52W Change-31.1%
ROE-66.9%
Analysis

The company holds $51.9M in cash, though total debt stands at $71.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$5.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -66.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $141.8M (2022) to $212.7M (2025), reflecting a 50% increase over the period.

The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Treace Medical Concepts, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms